Comparative safety of pharmacologic treatments for persistent depressive disorder: A systematic review and network meta-analysis

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Meister, Ramona ^a   Von Wolff, Alessa ^a   Mohr, Hannes ^a   Härter, Martin ^a   Nestoriuc, Yvonne ^b   Hölzel, Lars ^c   Kriston, Levente ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LEVACECARNINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; CLINICAL DECISION MAKING; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEALTH CARE NEED; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERSISTENT DEPRESSIVE DISORDER; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WAKEFULNESS; WEIGHT GAIN; WEIGHT REDUCTION; COMPARATIVE STUDY;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS;

EID: 84969235348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153380     Document Type: Review

References (52)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and ageof-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005; 62: 593-602. PMID: 15939837
2. Klein DN. Chronic depression: diagnosis and classification. Curr Dir Psychol Sci. 2010; 19: 96-100.
3. Torpey DC, Klein DN. Chronic depression: update on classification and treatment. Curr Psychiatry Rep. 2008; 10: 458-464. PMID: 18980728
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth ed. (DSM 5). Arlington: American Psychiatric Publishing; 2013.
5. De Lima MS, Moncrieff J, Soares B. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev. 2005; 2:CD001130.
6. De Lima MS, Hotopf M. A comparison of active drugs for the treatment of dysthymia. Cochrane Database Syst Rev. 2003; §:CD004047. PMID: 12918001
7. Kocsis JH, Rush AJ, Markowitz JC, Borian FE, Dunner DL, Koran LM, et al. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull. 2003; 37: 73-87. PMID: 15131518
8. Michalak EE, Lam RW, FRCPC. Breaking the myths: new treatment approaches for chronic depression. Can J Psychiatry. 2002; 47: 635-643. PMID: 12355675
9. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third ed. American Psychiatric Association, editor. Arlington (VA): American Psychiatric Association; 2010.
10. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, et al. (eds) for the Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression Langfassung, 2. Auflage, Vers 1.2015. Available from: www.depression.versorgungsleitlinien.de; [cited: 12.04.2016]; doi: 10.6101/ AZQ/000262
11. Kriston L, von Wolff A, Westphal A, Hölzel LP&z.ast;, Härter M&z.ast; (&z.ast;with equal contribution). Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014; 31: 621-630. doi: 10.1002/da.22236 PMID: 24448972
12. National Institute for Health and Clinical Excellence (NICE), editor. Depression: the Treatment and Management of Depression in Adults. National Clinical Practice Guideline 90. London: National Institute for Health and Clinical Excellence (NICE); 2009.
13. Von Wolff A, Hölzel LP, Westphal A, Härter M, Kriston L. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013; 144: 7-15. doi: 10.1016/j.jad.2012.06.007 PMID: 22963896
14. Kriston L, von Wolff A, Westphal A, Hölzel LP, Härter M. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014; 31: 621-30. doi: 10.1002/da.22236 PMID: 24448972
15. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester: The Cochrane Collaboration; 2011.
16. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al. Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder-An Updated Meta-analysis. Ann Intern Med. 2013; 155: 772-785.
17. Kessler TM, Bachmann LM, Minder C, Löhrer D, Umbehr M, Schünemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011; 6: e16718. doi: 10.1371/journal.pone.0016718 PMID: 21373193
18. Trindade E, Menon D, Topfer L-A, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assoc J. 1998; 159: 1245-1252.
19. Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004; 37 Suppl 1: S39-45. PMID: 15052513
20. Brambilla P, Cipriani a, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005; 38: 69-77. PMID: 15744630
21. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry. 2004; 754-762. PMID: 15290699
22. Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother. 2000; 1: 917-33. PMID: 11249500
23. Shedden Mora M, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc. 2011; 366: 1879-88.
24. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 2010; 62: 791-9.
25. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002; 287: 622-627. PMID: 11829702
26. Jakovljevic M. The placebo-nocebo response: Controversies and challenges from clinical and research perspective. Eur Neuropsychopharmacol. Elsevier; 2014; 24: 333-341.
27. McFarland BR, Klein DN. Mental health service use by patients with dysthymic disorder: treatment use and dropout in a 7 1/2-year naturalistic follow-up study. Compr Psychiatry. 2005; 46: 246-253. PMID: 16175754
28. Klein DN, Schwartz JE, Rose S, Leader JB. Five-year course and outcome of dysthymic disorder: a prospective, naturalistic follow-up study. Am J Psychiatry. 2000; 157: 931-939. PMID: 10831473
29. Bet PM, Hugtenburg JG, Penninx BWJH, Hoogendijk WJG. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013; 23: 1443-1451. doi: 10.1016/ j.euroneuro.2013.05.001 PMID: 23726508
30. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996; 93: 381-388. PMID: 8792909
31. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005; 66: 96-106. doi: 10.1016/j.curtheres.2005.04.006 PMID: 24672116
32. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitora: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994; 9: 47-53. PMID: 8195583
33. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015; 162: 777. doi: 10.7326/M14-2385 PMID: 26030634
34. Kriston L, von Wolff A, Hölzel L. Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: a systematic review (METACHRON). BMC Psychiatry. 2010; 10: 95. doi: 10.1186/1471-244X-10-95 PMID: 21092304
35. Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, Smith DH, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010; 63: 502-12. doi: 10.1016/j.jclinepi.2008.06.007 PMID: 18823754
36. Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoeconomics Outcomes Res. 2002; 2: 367-379.
37. Sankey SS, Weissfeld LA, Fine MJ, Kapoor W. An assessment of the use of the continuity correction for sparse data in meta-analysis. Commun Stat-Simul Comput. 1996; 25: 1031-1056.
38. Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012; 3: 312-324. doi: 10.1002/jrsm.1058 PMID: 26053424
39. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013; 13: 35. doi: 10.1186/1471-2288-13-35 PMID: 23496991
40. Rücker G, Schwarzer G, Krahn U, König J. netmeta: Network meta-analysis with R. 2014. Available: http://cran.r-project.org/web/packages/netmeta/netmeta.pdf
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88. PMID: 3802833
42. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2009.
43. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010; 36: 1-48.
44. Viechtbauer W. metafor: meta-analysis package for R. 2014. Available: http://cran.r-project.org/web/ packages/metafor/metafor.pdf
45. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine. Eur Psychiatry. 1996; 11: 135s-140s.
46. Boyer P, Lecrubier Y, Stalla-Bourdillon a, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999; 39: 25-32. PMID: 9892856
47. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997; 43: 95-103. PMID: 9165379
48. Rhebergen D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry. 2014; 27: 27-31. doi: 10.1097/YCO.0000000000000022 PMID: 24270481
49. Meister R, von Wolff A, Mohr H, Nestoriuc Y, Härter M, Hölzel L, et al. Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder. J Clin Epidemiol. in press.
50. Arnow BA, Blasey C, Manber R, Constantino MJ, Markowitz JC, Klein DN, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord. 2007; 97: 197-202. PMID: 16857266
51. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005; 18: 249-255. PMID: 16639148
52. Ioannidis J, Evans S, Gotzsche P, O'Neill R, Altman D, Schulz K, et al. Improving patient care better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004; 141: 781-788. PMID: 15545678